A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL

NCT07031700 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Relapsed/Refractory Follicular Lymphoma

Interventions

DRUG: Mosunetuzumab
DRUG: Tislelizumab

Sponsor

Tianjin Medical University Cancer Institute and Hospital